Lipocine Inc. (NASDAQ:LPCN) Short Interest Down 21.0% in December

Lipocine Inc. (NASDAQ:LPCN) was the recipient of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 48,500 shares, a drop of 21.0% from the December 15th total of 61,400 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average daily volume of 29,800 shares, the short-interest ratio is currently 1.6 days.

Lipocine Stock Performance

Shares of LPCN traded down $0.08 during mid-day trading on Friday, hitting $4.37. 42,027 shares of the company’s stock were exchanged, compared to its average volume of 29,612. The stock’s 50-day moving average is $4.89 and its 200-day moving average is $5.04. Lipocine has a fifty-two week low of $3.20 and a fifty-two week high of $11.79. The company has a market cap of $23.38 million, a price-to-earnings ratio of -5.75 and a beta of 1.23.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter. As a group, equities research analysts anticipate that Lipocine will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on LPCN shares. Alliance Global Partners assumed coverage on Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price target on the stock. StockNews.com assumed coverage on Lipocine in a report on Friday. They issued a “hold” rating on the stock.

Institutional Trading of Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP bought a new position in shares of Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.